Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
saRNA Influenza Vaccines: Findings and Boundaries
2026-10-12
The supplied 2026 study reports stronger and more durable immune responses for a self-amplifying RNA influenza vaccine than for conventional mRNA in mouse models, particularly against influenza B. The findings are promising but remain preclinical, formulation-specific, and insufficient to establish human effectiveness or safety. DNase I (RNase-free) is discussed separately as a DNA-cleaving reagent; the cited vaccine study does not document its use.
Doxycycline Nanomedicine for AAA: Evidence and Limits
2026-10-11
A 2025 preclinical study reports that cRGD-functionalized tea polyphenol nanoparticles can improve lesion-associated delivery of doxycycline in abdominal aortic aneurysm models. The findings are promising but remain preliminary: they do not establish clinical efficacy, long-term safety, or applicability to human aneurysm management.
Shufeng Xingbi Therapy, Gut Flora, and AR
2026-10-10
A 2025 bioRxiv preprint examines how Shufeng Xingbi Therapy may improve ovalbumin-associated allergic rhinitis in rats through coordinated changes in nasal inflammatory signaling, serum mediators, short-chain fatty acids, and intestinal microbial composition. Its main contribution is an integrated microbiome–immune framework, although the findings remain preliminary because the study was not peer reviewed and used a small animal cohort.
S-Adenosylmethionine: From Cofactor to Strategy
2026-10-09
Ademetionine is more than a methyl donor: it is a strategic lens for understanding substrate selectivity, pathway control, and translational assay design. New findings on the mulberry methyltransferase MaMT4 show why SAM-dependent biology must be interpreted through enzyme context, not cofactor availability alone.
Batimastat (BB-94): MMP Evidence Across Biology
2026-10-09
Batimastat (BB-94) is a broad-spectrum matrix metalloproteinase inhibitor with established preclinical relevance in cancer research, but its relationship to neuromuscular-junction development remains a research question rather than a demonstrated application. The strongest supplied evidence concerns muscle-derived BDNF, its localized release, and proteolytic processing—not direct testing of Batimastat in the reported synaptic models.
TRIM21–ERK1/2 Signaling in Pituitary Adenomas
2026-10-08
A 2025 Neuro-Oncology study identifies TRIM21 as an E3 ligase that connects K27-linked ubiquitination of ERK1/2 with phosphorylation, pituitary adenoma proliferation, and dopamine-agonist resistance. Its drug-screening results nominate Quisinostat and Fimepinostat as research candidates for reducing TRIM21, but the findings remain preclinical and require independent validation.
Ranolazine and HBV: Five Evidence Questions
2026-10-08
This evidence-focused overview separates the established pharmacology of Ranolazine from a 2025 mechanistic study of hepatitis B surface antigen, TBK1 signaling, interferon suppression and incomplete autophagy. It explains what the findings support, what they do not establish, and where applicability remains limited.
Targeted Doxycycline Nanoparticles for AAA Therapy
2026-10-07
A 2025 ACS Applied Materials & Interfaces study developed cRGD-functionalized tea polyphenol nanoparticles carrying Doxycycline for targeted treatment of abdominal aortic aneurysm. The preclinical platform reportedly increased lesion accumulation, enabled ROS-responsive release, addressed several AAA-associated pathways, and reduced model-associated hepatic and renal toxicity, while remaining unvalidated for human treatment.
Exendin-4 Research: Mechanism, Findings and Limits
2026-10-07
Exendin-4, also known as Exenatide, is a GLP-1 receptor agonist used in beta cell function research and type 2 diabetes research. This overview examines its biological context, the findings of a 2024 yeast-expression study, the difference between immunoreactive protein detection and demonstrated biological activity, and the limitations that constrain claims about affordability, oral delivery, and therapeutic translation.
IL-7 and Viral ER Proteostasis: A Translational Lens
2026-10-06
A mechanistic perspective on how SARS-CoV-2 papain-like protease reshapes ER-associated protein regulation—and why IL-7 should be evaluated as an immune-context variable rather than presumed antiviral therapy. The analysis separates reported findings from translational hypotheses and defines where recombinant human IL-7 may support future research.
Phytol and RXR Signaling: An Evidence-First View
2026-10-06
Phytol connects retinoid X receptor signaling with metabolism, GABAergic transmission modulation, and important chemical-identity questions. This evidence-first analysis also explains what a shaped bottlebrush polymer study can—and cannot—teach us about interpreting molecular biology data.
Phytol: Evidence, Receptor Biology, and Research Limits
2026-10-05
A source-grounded overview of Phytol, including reported RXR activity, metabolism, GABAergic claims, antischistosomal research context, trans-Phytol limitations, and the boundaries of the supplied evidence.
SARS-CoV-2 NSP15 Inhibitor Screening: Study Insights
2026-10-05
Vijayan and Gourinath combined structure-based virtual screening with molecular dynamics simulations to prioritize natural products predicted to bind the SARS-CoV-2 NSP15 endoribonuclease. Thymopentin and oleuropein emerged as leading computational candidates, but the findings remain hypothesis-generating because biochemical, cellular, pharmacokinetic, and clinical validation was not reported.
Atorvastatin Beyond Lipids: A Translational Evidence Map
2026-10-04
Atorvastatin is more than an HMG-CoA reductase inhibitor: this evidence-focused review connects cholesterol metabolism research with ferroptosis, liver cancer, and vascular biology while separating preclinical promise from established conclusions.
Recombinant Annexin V Purification: Evidence from 1993
2026-10-03
Burger and colleagues reported a rapid purification strategy for recombinant annexin V that combined gentle bacterial cell opening, calcium-dependent liposome binding, and ion-exchange chromatography. The study’s main contribution was a practical route to highly pure protein for crystallography, electron microscopy, spectroscopy, and single-channel measurements, although its evidence is specific to annexin V and the analytical standards of the early 1990s.